2025
Oculis’ Novel Peptidomimetic OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis
Oculis, OCS-05, Peptidomimetic, Acute Optic Neuritis, Neuroprotective Therapy, Phase 2 Trial, ACUITY Trial
Merck Acquires WuXi Biologics’ Irish Vaccine Facility in $500M Deal
Merck, WuXi Biologics, vaccine facility, Ireland, $500M deal, pharmaceutical manufacturing
Orbis Medicines Secures €90 Million Series A Funding to Revolutionize Oral Macrocycle Drug Discovery
Orbis Medicines, Series A funding, oral macrocycle drugs, nCycles, biologic drug alternatives, pharmaceutical innovation
I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig
I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers
Citius Oncology Explores Strategic Alternatives Ahead of LYMPHIR Commercial Launch
Citius Oncology, LYMPHIR, strategic alternatives, commercial launch, cutaneous T-cell lymphoma, immunotherapy
Orbis Kicks Off 2025 with €90M Series A Funding in Fierce Biotech Fundraising Tracker
Fierce Biotech Fundraising Tracker 2025, Orbis Series A Funding, Biotech Venture Capital, 2025 Biotech Investments, Series A Funding Rounds
I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space
I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development
Novo Nordisk Seeks FDA Restriction on Victoza Compounding Amid Ongoing GLP-1 Supply Issues
Novo Nordisk, FDA, Victoza, liraglutide, compounding, GLP-1, supply issues, pharmaceutical regulation
2024 FDA Drug Approvals: A Year of Strategic Approvals and Long-Awaited Treatments
FDA drug approvals 2024, novel drug approvals, accelerated approvals, cancer treatments, rare disease therapies
2024 FDA Drug Approvals: Small Companies Make Significant Impact
FDA drug approvals 2024, small biotech companies, pharmaceutical industry, new drug approvals, regulatory updates.